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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
standardised aqueous extract from white kidney bean (Phaseolus 
vulgaris L.) and reduction of body weight pursuant to Article 13(5) of 
Regulation (EC) No 1924/2006
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from InQpharm Europe Ltd, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific 
substantiation of a health claim related to a standardised aqueous extract from white kidney bean (Phaseolus 
vulgaris L.) and reduction of body weight. The Panel considers that the food is sufficiently characterised. A 
reduction in body weight is a beneficial physiological effect for overweight individuals. The applicant identified 
a total of four human intervention studies which investigated the effects of the aqueous extract from white kidney 
bean on body weight as being pertinent to the claim. No conclusions could be drawn from two of these four 
studies. In weighing the evidence, the Panel took into account that one human intervention study showed an 
effect of the standardised aqueous extract from white kidney bean in reducing body weight when consumed for 
12 weeks, that the reduction in body weight was mostly through a reduction in body fat and that the effect of the 
standardised aqueous extract from white kidney bean on body weight was supported by a second study of shorter 
duration. However, the Panel also took into account that the first study was at risk of bias, that the supportive 
study suffered from methodological limitations and that no evidence was provided for a mechanism by which the 
standardised aqueous extract from white kidney bean could exert the claimed effect. The Panel concludes that the 
evidence provided is insufficient to establish a cause and effect relationship between the consumption of the 
standardised aqueous extract from white kidney bean (Phaseolus vulgaris L.) and reduction of body weight. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from InQpharm Europe Ltd, submitted for authorisation of a health claim 
pursuant  to  Article 13(5)  of  Regulation  (EC)  No  1924/2006  via  the  Competent  Authority  of  the 
United Kingdom, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to 
deliver an opinion on the scientific substantiation of a health claim related to a standardised aqueous 
extract from white kidney bean (Phaseolus vulgaris L.) and reduction of body weight. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The  food  that  is  the  subject  of  the  health  claim  is  an  aqueous  extract  from  white  kidney  bean 
(Phaseolus vulgaris L.) standardised to its content of α-amylase inhibitor. The extract and tablets 
made thereof are marketed under the brand names Glucosanol™, Glycolite™, Phase 2
®, PhaseLite™ 
and  Starchlite™.  The  Panel  considers  that  the  food,  an  aqueous  extract  from  white  kidney  bean 
(Phaseolus vulgaris L.) standardised by its α-amylase inhibitory activity (Glucosanol™, Glycolite™, 
Phase 2
®,  PhaseLite™,  Starchlite™),  which  is  the  subject  of  the  health  claim,  is  sufficiently 
characterised in relation to its in vitro α-amylase inhibitory activity. 
The claimed effect is “helps to reduce body weight”. The target population proposed by the applicant 
is “the general population that wants to lose or manage their weight”. The Panel considers that a 
reduction in body weight is a beneficial physiological effect for overweight individuals. 
The applicant identified a total of four human intervention studies, which investigated the effects of 
the aqueous extract from white kidney bean on body weight, as being pertinent to the claim. 
Two  double-blind,  randomised,  placebo-controlled,  parallel  intervention  studies  that  assessed  the 
effects of the aqueous extract from white kidney bean on body weight, body fat and waist and hip 
circumferences, and on subjective ratings of hunger, appetite and “energy level”, were claimed by the 
authors  to  be  underpowered  with  respect  to  differences  in  body  weight  changes  between  the 
intervention and control groups based on post-hoc power calculations. None of the studies reported an 
effect of the aqueous extract from white kidney bean on any of the outcome measures considered. The 
Panel considers that no conclusions can be drawn from these studies for the scientific substantiation 
of the claim. 
In a randomised, placebo-controlled, two-centre parallel study that was planned to be double-blind, 
124 subjects were randomised to consume the aqueous extract from white kidney bean (n = 62; mean 
body  weight  85.0 kg)  or  a  placebo  (n =  62;  mean  body  weight  85.9 kg)  daily for  12 weeks. The 
subjects were instructed to ingest either the aqueous extract from white kidney bean (3 g per day) or a 
placebo 30 minutes before their main meals. The primary outcome of the study was differences in 
body weight changes between study groups at week 12. Changes in waist and hip circumferences and 
in body fat and fat-free mass were assessed inter alia as secondary outcomes. One subject dropped 
out of the study. The Mann-Whitney U-test was used for between-group comparisons. An interim 
analysis with un-blinding took place after 50 % of the subjects had finished the study, in order to 
check whether sample size calculations were correct. Results were provided for the intention-to-treat 
(ITT; n = 123) population and for the per protocol (PP; n = 117) population. Considering the ITT 
population, at week 12 the subjects in the group who had consumed the kidney bean extract lost 
significantly more weight than subjects in the placebo group (results in mean ± standard deviation 
(SD): -2.91 kg ± 2.63 vs. -0.92 kg ± 2.00; p < 0.001). This change was mostly attributed to a loss of 
body fat. Statistically significant differences were also reported for changes in waist circumference 
and hip circumference. There were no statistically significant differences between the groups for 
changes in fat-free mass. Energy intake and physical activity levels were not significantly different 
between the groups at any time point. Analysis of the PP population showed similar results on weight 
loss. Sensitivity analyses confirmed the results of the primary analysis.  The Panel notes that this Standardised aqueous extract from white kidney bean and reduction of body weight 
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study,  which  had  a  risk  of  bias  through  un-blinding,  showed  a  decrease  in  body  weight  after 
consumption of the food for 12 weeks. 
In a double-blind, randomised, placebo-controlled trial, 101 subjects recruited in Hangzhou, China, 
were randomised to receive 1 000 mg of the aqueous extract from white kidney bean (n = 51, mean 
body weight 79.2 kg) or a placebo (n = 50, mean body weight 81.3 kg), taken three times per day 
(before each meal) for 60 days. Body weight and waist and hip circumferences were measured at 
baseline and on days 30 and 60 of the study. Differences in changes in body weight between the two 
study groups were analyses by t-test, which did not take into account the repeated measures design of 
the study. At day 60, the subjects in the kidney bean extract group had lost significantly more weight 
than the subjects in the placebo group (mean ± standard error of the mean (SEM): -1.9 kg ± 0.15 vs. 
-0.4 kg ± 0.13; p < 0.001). Significant findings were also reported for changes in waist circumference. 
The Panel considers that this study, which had methodological limitations, showed a reduction in 
body weight after consumption of the food for about eight weeks. 
The applicant claims that the standardised aqueous extract from white kidney bean could exert the 
claimed effect by (i) inhibiting pancreatic α-amylase activity in vivo, which would reduce digestion of 
starch  and  thereby  absorption  of  dietary  complex  glycaemic  carbohydrates;  (ii)  delaying  gastric 
emptying; and (iii) reducing feelings of hunger. The Panel notes that no evidence was provided for a 
mechanism  by  which  the  standardised  aqueous  extract  from  white  kidney  bean  could  exert  the 
claimed effect in vivo in humans. 
In weighing the evidence, the Panel took into account that one human intervention study showed an 
effect of the standardised aqueous extract from white kidney bean in reducing body weight when 
consumed for 12 weeks, that the reduction in body weight was mostly through a reduction in body fat, 
and that the effect of the standardised aqueous extract from white kidney bean on body weight was 
supported by a second study of shorter duration. However, the Panel also took into account that the 
first study was at risk of bias, that the supportive study suffered from methodological limitations and 
that no evidence was provided for a mechanism by which the standardised aqueous extract from white 
kidney bean could exert the claimed effect. 
The  Panel  concludes  that  the  evidence  provided  is  insufficient  to  establish  a  cause  and  effect 
relationship between the consumption of the standardised aqueous extract from white kidney bean 
(Phaseolus vulgaris L.) and reduction of body weight. Standardised aqueous extract from white kidney bean and reduction of body weight 
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BACKGROUND 
Regulation (EC) No 1924/2006
4 harmonises the provisions that relate to nutrition and health claims , 
and establishes rules governing the Community authorisation of h ealth claims made on foods.  As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of  
this Regulation, are authorised in accordance with this Regulation , and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular,  Article 13(5) of this  
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to chi ldren’s  development  and  health)  which  are  based  on  newly  developed 
scientific  evidence,  or  which  include  a  request  for  the  protection  of  proprietary  data,  to  the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted  claims  referred  to  in  Article 13(3)  shall  be  submitted  by  the  applicant  to  the  national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
  The application was received on 02/12/2013. 
  The  scope  of  the  application  was  proposed  to  fall  under  a  health  claim  based  on  newly 
developed  scientific  evidence.  The  application  included  a  request  for  the  protection  of 
proprietary data. 
  On 23/01/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
  On 28/01/2014, EFSA received the missing information as submitted by the applicant. 
  The scientific evaluation procedure started on 30/01/2014. 
  On 06/03/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was  stopped  on  17/03/2014  and  was  restarted  on  01/04/2014,  in  compliance  with 
Article 18(3) of Regulation (EC) No 1924/2006. 
  On  02/04/2014,  EFSA  received  the  requested  information  (which  was  made  available  to 
EFSA in electronic format on 31/03/2014). 
  During  its  meeting  on  25/06/2014,  the  NDA  Panel,  having  evaluated  the  data  submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a standardised 
aqueous  extract  from  white  kidney  bean  (Phaseolus  vulgaris  L.)  and  reduction  of  body 
weight. 
TERMS OF REFERENCE 
EFSA  is  requested  to  evaluate  the  scientific  data  submitted  by  the  applicant  in  accordance  with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: standardised aqueous extract 
(Glucosanol™, Glycolite™, Phase 2
®, PhaseLite™, Starchlite™) from white kidney bean (Phaseolus 
vulgaris L.) and reduction of body weight. 
                                                       
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. Standardised aqueous extract from white kidney bean and reduction of body weight 
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EFSA DISCLAIMER 
The  present  opinion  does  not  constitute,  and  cannot  be  construed  as,  an  authorisation  for  the 
marketing of the standardised aqueous extract from white kidney bean, a positive assessment of its 
safety or a decision on whether the standardised aqueous extract from white kidney bean is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. Standardised aqueous extract from white kidney bean and reduction of body weight 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s  name  and  address:  InQpharm  Europe  Ltd,  Invision  House,  Wilbury  Way,  Hitchin, 
Hertfordshire SG4 0TY, United Kingdom. 
The application includes a request for the protection of proprietary data for two unpublished study 
reports (Chong, 2012; Chong and Beah, 2013), in accordance with Article 21 of Regulation (EC) No 
1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is PhaseLite™, which is a 
proprietary standardised aqueous extract from white kidney bean (Phaseolus vulgaris L.). 
The  applicant  indicated  that  PhaseLite™  is  contained  in/marketed  as  Glucosanol™,  Glycolite™, 
Phase 2
®, PhaseLite™ and Starchlite™. 
Health relationship as claimed by the applicant 
According  to  the  applicant,  the  consumption  of  PhaseLite™  helps  to  reduce  body  weight  in 
overweight or obese people. The mechanism proposed by the applicant is the inhibition of pancreatic 
α-amylase by α-amylase inhibitor isoform 1 (α-AI1), contained in PhaseLite™. This inhibition would 
lead to a reduction in starch digestion and absorption, delayed gastric emptying and a lower sense of 
hunger, overall resulting in reduced body weight. 
Wording of the health claim as proposed by the applicant 
The  applicant  has  proposed  the  following  wording  for  the  health  claim:  “Helps  to  reduce  body 
weight”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 1 g PhaseLite™ three times daily, approximately 30 minutes 
before main meals. The proposed target population is the “general population that wants to lose or 
manage their weight”. 
ASSESSMENT 
1.  Characterisation of the food/constituent 
The  food  that  is  the  subject  of  the  health  claim  is  an  aqueous  extract  from  white  kidney  bean 
(Phaseolus vulgaris L.) standardised to its content of α-amylase inhibitor (i.e. at least 3 000 α-amylase 
inhibiting units (AAIU)/g). 
The α-amylase inhibitor was indicated to be α-amylase inhibitor isoform 1 (α-AI1), which is the most 
widely  distributed  of  the  isoforms  and  is  found  in  most  of  the  common  bean  cultivars  grown 
worldwide (Obiro et al., 2008). 
An  overview  of  the  manufacturing  process  and  information  on  the  stability  and  batch-to-batch 
analyses were provided. Standardised aqueous extract from white kidney bean and reduction of body weight 
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The applicant claims that the specific manufacturing process (confidential information) results in an 
increased stability of the extract in acidic conditions (such as those prevailing in the stomach and 
duodenum), so that its inhibitory activity on pancreatic α-amylase would be different from that of 
other (generic) white kidney bean aqueous extracts, as suggested by the maintenance of the α-amylase 
inhibitory activity of the extract in vitro after being exposed to acidic conditions mimicking those of 
the gastrointestinal tract, as compared to other extracts. 
The extract (an off-white to beige homogeneous powder) and tablets made thereof (i.e. extract plus 
excipients) are marketed under the brand names Glucosanol™, Glycolite™, Phase 2
®, PhaseLite™ 
and Starchlite™. 
The Panel considers that the food, an aqueous extract from white kidney bean (Phaseolus vulgaris L.) 
standardised by its α-amylase inhibitory activity (Glucosanol™, Glycolite™, Phase 2
®, PhaseLite™, 
Starchlite™), which is the subject of the health claim, is sufficiently characterised in relation to its 
in vitro α-amylase inhibitory activity. 
2.  Relevance of the claimed effect to human health 
The claimed effect is “helps to reduce body weight”. The target population proposed by the applicant 
is “the general population that wants to lose or manage their weight”. 
A reduction in body weight is considered a beneficial physiological effect for adults with an excess 
body weight, if body fat is reduced (EFSA NDA Panel, 2012). 
The Panel considers that a reduction in body weight is a beneficial physiological effect for overweight 
individuals. 
3.  Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline, using the search terms “standardized extract 
from  white kidney bean (Phaseolus vulgaris)”, “Phase 2
®”, “weight management”, “weight loss”, 
“body weight”, “α-amylase inhibitor from white kidney beans”, “human”, “study” and “trial”. The 
search was limited to publications in the English language. Studies were included if they were of 
“sound design” (i.e. randomised controlled trials) and were concerned with weight loss in overweight 
and  obese  subjects  or  supported  the  mode  of  action  (mechanism)  of  PhaseLite™,  Phase 2
®, 
Starchlite™,  Glucosanol™  or  Glycolite™.  Studies  focusing  on  aspects  other  than  weight 
management/loss,  studies  using  raw  kidney  bean  preparations  or  bean  varieties  other  than  white 
kidney  bean  and  studies  using  combinations  of  α-amylase  inhibitor  plus  lectins  or  other  food 
ingredients (e.g. vitamins and minerals) were excluded. 
Human intervention studies 
The applicant identified a total of four human intervention studies which investigated the effects of an 
aqueous extract from white kidney bean (complying with the specifications indicated in section 1) on 
body weight as being pertinent to the claim (Udani et al., 2004; Udani and Singh, 2007; Wu et al., 
2010; Chong, 2012, unpublished study report, claimed as proprietary by the applicant, and published 
by Grube et al., 2013). 
Two double-blind, randomised, placebo-controlled, parallel intervention studies (Udani et al., 2004; 
Udani and Singh, 2007) that assessed the effects of the aqueous extract from white kidney bean on 
body weight, body fat and waist and hip circumferences, and on subjective ratings of hunger, appetite 
and “energy level”, were claimed by the authors to be underpowered with respect to differences in 
body  weight  changes  between  the  intervention  and  control  groups  based  on  post-hoc  power 
calculations.  The  study  by  Udani  et  al.  (2004)  randomised  39  adult  subjects  to  consume  either Standardised aqueous extract from white kidney bean and reduction of body weight 
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1 500 mg of the aqueous extract from white kidney bean (n = 20) or placebo (n = 19) twice daily for 
eight weeks. The second study (Udani and Singh, 2007) randomised 25 adult subjects to consume 
either 1 000 mg of the aqueous extract from white kidney bean (n = 13) or placebo (n = 12) twice 
daily for four weeks. Neither of the studies reported an effect of the aqueous extract from white 
kidney bean on any of the outcome measures considered. The Panel notes that these studies were 
claimed by the authors to be underpowered to assess changes in body weight. The Panel considers 
that no conclusions can be drawn from these studies for the scientific substantiation of the claim. 
In a randomised, placebo-controlled, two-centre parallel study which was planned to be double-blind, 
(Chong, 2012, unpublished study report, claimed as proprietary by the applicant; Grube et al., 2013) 
124 subjects  (91 female,  32  male;  mean  age  46 ± 10.1 years)  were  randomised  to  consume  the 
aqueous extract from white kidney bean (n = 62; mean body weight 85.0 ± 11.3 kg) or a placebo (inert 
tablet excipients; n = 62; mean body weight 85.9 ± 10.1 kg) daily for 12 weeks. Inclusion criteria 
were body mass index (BMI) between 25 and 35 kg/m
2 and a stable body weight three months prior to 
the study. Randomisation was stratified to ensure equal distribution of overweight and obese subjects 
(cut-off at BMI ≥ 30 kg/m
2) between the study groups. The subjects were instructed to ingest six 
tablets per day of either the aqueous extract from white kidney bean (500 mg/tablet; 3 g per day) or 
placebo, i.e. two tablets three times per day 30 minutes before their main meals (breakfast, lunch and 
dinner). In addition, all subjects were instructed to maintain a “mildly hypo-caloric” diet (energy 
deficit  of  500 kcal  per  day)  providing  approximately  40 %  of  energy  from  “starchy”  foods. 
Participants were also encouraged to gradually increase their physical activity. The 12-week study 
period was preceded by a 2-week run-in period during which subjects consumed the placebo. Energy 
intakes and physical activity levels (using the International Physical Activity Questionnaire (IPAQ)) 
of all subjects were assessed at all study visits, based on the subjects’ diaries (subjects recorded daily 
energy intakes and weekly physical activities). 
The primary outcome of the study was differences in body weight changes between study groups at 
week 12. Based on the results of previous studies, and assuming a drop-out rate of 20 %, 62 subjects 
per group were needed to detect changes in body weight with a power of 80 % (at a significance level 
of 5 %), assuming an effect size of 0.6. Changes in waist and hip circumferences, and in body fat and 
fat-free  mass  (calculated  from  bioelectrical  impedance  analysis  measurements),  were  assessed 
inter alia as secondary outcomes. Measurements were taken at the start of the run-in phase (week -2), 
at the beginning of the intervention (i.e. baseline, week 0) and at weeks 4, 8 and 12. One subject (from 
the placebo group) dropped out of the study (reasons not provided). The Mann-Whitney U-test was 
used for between-group comparisons. An interim analysis with un-blinding took place after 50 % of 
the subjects had finished the study, in order to check whether sample size calculations were correct. 
No  adjustment  of  sample  size  was  found  to  be  necessary  in  this  interim  analysis.  Results  were 
provided for the intention-to-treat (ITT) population (n = 123), i.e. all the randomised subjects without 
the one drop-out, and for the per protocol (PP) population (n = 117), i.e. subjects with at least 80 % 
compliance (which led to the exclusion of six subjects, four from the placebo group and two from the 
kidney bean extract group). Considering the ITT population, at week 12 the subjects in the group who 
had consumed the kidney bean extract had lost significantly more weight than subjects in the placebo 
group (results in mean ± SD: -2.91 kg ± 2.63 vs. -0.92 kg ± 2.00; p < 0.001). This change was mostly 
attributed  to  a  loss  of  body  fat  (kidney  bean  extract:  -2.23 kg  ± 2.16;  placebo:  -0.65 kg  ± 2.33; 
p < 0.001). Statistically significant differences were also reported for changes in waist circumference 
(kidney bean extract: -2.50 cm ± 2.25; placebo: -0.90 cm ± 2.13; p < 0.001) and hip circumference 
(kidney  bean  extract:  -2.34 cm  ±  2.13;  placebo:  -0.84 cm  ± 1.42;  p < 0.001).  There  were  no 
statistically significant differences between the groups for changes in fat-free mass. Energy intake and 
physical activity levels were not significantly different between the groups at any time point. Analysis 
of the PP population showed similar results for weight loss (kidney bean extract: -3.01 kg ± 2.59; 
placebo: -0.95 kg ± 2.05; p < 0.001). 
EFSA requested the applicant to clarify whether, and how, the repeated measures design of the study 
was taken into account in the analysis, and, if this was not the case, to provide a sensitivity analysis Standardised aqueous extract from white kidney bean and reduction of body weight 
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taking into account the design of the study. In reply, the applicant provided two analyses: (i) a non-
parametric  multivariate  analysis  of  longitudinal  data  (i.e.  non-parametric  multivariate  analysis  of 
variance  (MANOVA)  for  repeated  measures);  and  (ii)  a  non-parametric  multivariate  analysis  of 
covariance for repeated measures (MANCOVA) with baseline data as covariate. For the MANCOVA, 
only data from subjects with complete observations were used (i.e. seven subjects were excluded). 
These sensitivity analyses confirmed the results of the primary analysis. The Panel notes that this 
study,  which  had  a  risk  of  bias  through  un-blinding,  showed  a  decrease  in  body  weight  after 
consumption of the food for 12 weeks. 
In a double-blind, randomised, placebo-controlled trial (Wu et al., 2010), 101 subjects recruited in 
Hangzhou, China, were randomised to receive 1 000 mg of the aqueous extract from white kidney 
bean  (n = 51,  27  females;  mean  bodyweight  79.2 kg  ± 1.6  (SEM)) or a placebo (microcrystalline 
cellulose; n = 50, 19 females; mean bodyweight 81.3 kg ± 1.7 (SEM)), taken 15 minutes before each 
meal (i.e. three times per day) for 60 days. Body weight and waist and hip circumferences were 
measured at baseline and at days 30 and 60 of the study. Body fat content was not assessed. No power 
calculations  were  performed.  No  information  was  provided  on  the  subjects’  physical  activity  or 
background diet. Differences in changes in body weight between the two study groups were analyses 
by t-test, which did not take into account the repeated measures design of the study. At day 60, the 
subjects in the kidney bean extract group had lost significantly more weight than the subjects in the 
placebo group (-1.9 kg ± 0.15 (SEM) vs. -0.4 kg ± 0.13 (SEM); p < 0.001). Significant findings were 
also reported for changes in waist circumference (-1.9 cm ± 0.32 (SEM) vs. -0.4 cm ± 0.26 (SEM); 
p < 0.001).  The  Panel  considers  that  this  study,  which  had  methodological  limitations,  showed  a 
reduction in body weight after consumption of the food for about eight weeks. 
Mechanisms by which the food could exert the claimed effect 
The applicant claims that the standardised aqueous extract from white kidney bean could exert the 
claimed effect by (i) inhibiting pancreatic α-amylase activity in vivo, which would reduce digestion of 
starch  and  thereby  absorption  of  dietary  complex  glycaemic  carbohydrates;  (ii) delaying  gastric 
emptying; and (iii) reducing feelings of hunger. 
Out of the eight human intervention studies that were provided by the applicant in support of the 
mechanism by which the food could exert the claimed effect (Layer et al., 1985, 1986; Boivin et al., 
1987; Jain et al., 1989, 1991; Udani, et al., 2009; Vinson et al., 2009), only three (Udani, et al., 2009; 
Vinson et al., 2009 – reporting on two studies) were conducted with a white kidney bean extract 
complying with the specifications mentioned in section 1. Those studies addressed the effects of the 
standardised  aqueous  extract  from  white  kidney  bean  on  the  glycaemic  index  of  foods  or  meals 
containing complex carbohydrates. 
In a randomised, open-label, six-arm cross-over study (Udani, et al., 2009), glycaemic index testing 
was  performed  in  13 subjects  who  consumed  50 g  of  net  carbohydrates  in  white  bread  with  and 
without the addition of white kidney bean extract in capsule or powder form, each in dosages of 
1 500 mg,  2 000 mg  and  3 000 mg.  No  statistically  significant  effects  were  seen  when  the  white 
kidney bean extract was provided in capsule form. With regards to the powder form, a significant 
reduction  of  glycaemic  index  (-20.23  or  34.11 %;  p = 0.023)  was  seen  after  consumption  of  the 
highest  dose,  i.e.  3 000 mg,  but  not  for  the  1 500 mg  and  2 000 mg  doses.  Vinson  et  al.  (2009) 
reported  on  two  randomised,  double-blind,  cross-over,  single-dose  studies. In  the  first  study, 
11 fasting subjects were given four slices of white bread and 42 g of margarine (610 kcal from 60.5 g 
carbohydrates, 36.5 g fat and 10.5 g protein)  with or without  1 500 mg of the white kidney bean 
extract. Blood glucose concentrations were measured for two hours and the incremental areas under 
the curve (iAUC) were calculated from baseline to when the curves first returned to baseline. The 
iAUC was 66 % lower (p < 0.05) for the bean extract than for the control. The second study was 
carried out in seven subjects and included a full meal (630 kcal from 64 g carbohydrates, 29 g fat and 
29 g protein) consumed after an overnight fast with and without 750 mg of the bean extract. There Standardised aqueous extract from white kidney bean and reduction of body weight 
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were no significant differences in the iAUC between the meals consumed with or without the bean 
extract.  The  Panel  considers  that  these  studies  do  not  provide  evidence  for  an  effect  of  the 
standardised aqueous extract from white kidney bean in reducing the activity of pancreatic α-amylase 
in vivo which would lead to a decrease in carbohydrate digestion and absorption under the conditions 
of use proposed by the applicant and tested in the efficacy studies provided (Chong, 2012, and Grube 
et al., 2013; Wu et al., 2010). 
The Panel notes that no evidence was provided for an effect of the standardised aqueous extract from 
white kidney bean on the rate of gastric emptying. 
Three studies (Udani et al., 2004; Udani and Singh, 2007; Chong, 2012, and Grube et al., 2013) out of 
four human intervention studies that addressed the effects of the standardised aqueous extract from 
white kidney bean on body weight also reported subjective ratings of satiety, hunger and the overall 
tolerability of the product. No significant differences between the intervention and control groups 
were reported in relation to these outcomes in any of the studies (Udani et al., 2004; Udani and Singh, 
2007; Chong, 2012, and Grube et al., 2013). The Panel notes that the standardised aqueous extract 
from white kidney bean had no effect on subjective ratings of hunger or satiety. 
Out  of  the  three  animal  studies  (Tormo  et  al.,  2004,  2006;  Harikumar  et  al.,  2005),  one  study 
(Harikumar  et  al.,  2005)  was  performed  with  a  white  kidney  bean  extract  complying  with  the 
specifications mentioned in section 1. This study assessed the acute and sub-chronic toxicity, rather 
than the efficacy with respect to the claimed effect, of the white kidney bean extract in Wistar rats. 
The in vitro studies (Bowman, 1945; Marshall and Lauda, 1975; Bompard-Gilles et al., 1996; Le 
Berre-Anton  et  al.,  1997,  2000)  were  concerned  with  purification,  structural  analysis  and 
characterisation of binding properties of α-amylase inhibitor isolated from Phaseolus vulgaris. The 
Panel considers that no conclusions can be drawn from these studies with respect to the scientific 
substantiation of the claim. 
The Panel notes that no evidence has been provided for a mechanism by which the  standardised 
aqueous extract from white kidney bean could exert the claimed effect in vivo in humans. 
In weighing the evidence, the Panel took into account that one human intervention study showed an 
effect of the standardised aqueous extract from white kidney bean in reducing body weight when 
consumed for 12 weeks, that the reduction in body weight was mostly through a reduction in body fat, 
and that the effect of the standardised aqueous extract from white kidney bean on body weight was 
supported by a second study of shorter duration. However, the Panel also took into account that the 
first study was at risk of bias, that the supportive study suffered from methodological limitations and 
that no evidence was provided for a mechanism by which the standardised aqueous extract from white 
kidney bean could exert the claimed effect. 
The  Panel  concludes  that  the  evidence  provided  is  insufficient  to  establish  a  cause  and  effect 
relationship between the consumption of the standardised aqueous extract from white kidney bean 
(Phaseolus vulgaris L.) and reduction of body weight. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
  The food, an aqueous extract from white kidney bean (Phaseolus vulgaris L.) standardised by 
its  α-amylase  inhibitor  activity  (Glucosanol™,  Glycolite™,  Phase 2
®,  PhaseLite™, 
Starchlite™), which is the subject of the health claim, is sufficiently characterised. Standardised aqueous extract from white kidney bean and reduction of body weight 
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  The claimed effect is “helps to reduce body weight”. The target population proposed by the 
applicant is “the general population that wants to lose or manage their weight”. A reduction in 
body weight is a beneficial physiological effect for overweight individuals. 
  The evidence provided is insufficient to establish a cause and effect relationship between the 
consumption  of  the  standardised  aqueous  extract  from  white  kidney  bean  (Phaseolus 
vulgaris L.) and reduction of body weight. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a standardised aqueous extract (Glucosanol™, Glycolite™, Phase 2
®, 
PhaseLite™, Starchlite™) from white kidney bean (Phaseolus vulgaris L.) and reduction of body 
weight pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0403_UK). 
December 2013. Submitted by InQpharm Europe Ltd. 
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ABBREVIATIONS 
AAIU  α-amylase inhibiting units 
iAUC  incremental area under the curve 
ITT  intention to treat 
MANOVA  multivariate analysis of variance 
MANCOVA  multivariate analysis of covariance 
PP   per protocol 
SD  standard deviation 
SEM  standard error of the mean 
 